What is the impact of neoadjuvant chemoradiation on outcomes in gastro-intestinal cancer?
J Visc Surg
; 154(3): 185-195, 2017 Jun.
Article
en En
| MEDLINE
| ID: mdl-28602545
ABSTRACT
Multimodal therapeutic strategies combining chemotherapy, radiation therapy and surgery have been shown to be feasible and to have a positive impact on outcomes by decreasing the risk of locoregional recurrence and often by increasing overall survival. The advantages of neoadjuvant chemo(radio)therapy include optimal tumor control combined with better tolerance and compliance to treatment while also increasing the number of candidates for surgery. Whereas indications for neoadjuvant therapy are increasing, its impact on surgical treatment and postoperative outcomes are not well-known. Surgeons frequently believe that chemo(radio)therapy may amplify intraoperative difficulties, thereby increasing postoperative morbidity and mortality. The aim of this review was to report the state of the art regarding (i) the role of chemo(radio)therapy; (ii) its impact on surgical indications and modalities; and (iii) its impact on postoperative outcomes for the most frequently encountered gastro-intestinal cancers, i.e. esophageal, rectal, pancreatic, and anal canal cancer.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Adenocarcinoma
/
Quimioradioterapia
/
Neoplasias Gastrointestinales
Tipo de estudio:
Etiology_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
J Visc Surg
Asunto de la revista:
GASTROENTEROLOGIA
Año:
2017
Tipo del documento:
Article